SARS-CoV-2 Lambda variant

News and Video Search Results

News coverage

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

PR Newswire Asia 30 Mar 2022

The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab..

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)

PR Newswire Asia

16 Mar 2022

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

PR Newswire Asia

09 May 2022

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
GlobeNewswire 29 Mar 2022
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
GlobeNewswire 15 Mar 2022

0 shares 1 views

You might like

SARS-CoV-2 Lambda variant media coverage

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

GlobeNewswire 12 Jan 2022

Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other..

SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
GlobeNewswire 16 Dec 2021
ARISTA Biotech Confirms Antigen Test Effectiveness Against Omicron and other COVID variantsArista-table2.jpeg
Media OutReach 15 Dec 2021
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
PR Newswire Asia 08 Dec 2021
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
GlobeNewswire 29 Nov 2021

Advertisement

More coverage

Smiths Detection confirms BioFlash detects airborne SARS-CoV-2 variants including Delta and Delta plus

Business Wire 13 Oct 2021

LONDON--(BUSINESS WIRE)--Smiths Detection, a global leader in threat detection and security screening technologies, today confirms..